Testing benralizumab for uncontrolled eosinophilic asthma
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 75 years old.
- You have moderate to severe asthma that is not well controlled with your current medium-dose inhaler (ICS/LABA).
- You have had at least 2 asthma flare-ups in the past year that needed treatment with steroid pills or a hospital visit.
- You have a blood test showing a high level of eosinophils (a type of white blood cell) – at least 150 cells per microliter.
- You are not a current smoker and have not been a heavy smoker in the past (smoking history less than 10 pack-years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called KT-621 for people with moderate to severe eosinophilic asthma. It aims to see if the drug can help control asthma better than the standard inhaled treatments alone.
This study tests a new way to take asthma medicine using a device that tracks your inhaler use. If you already use Fasenra (benralizumab) for severe asthma, you may be able to join.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
This study looks at people in China with severe eosinophilic asthma who are starting a new medicine called benralizumab. It will collect information about their symptoms and quality of life to understand who benefits most.
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
Hear when a new Eosinophilic Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.